Recursion Pharmaceuticals Inc. published its 2025 annual report, outlining progress in advancing its AI-native drug discovery and development platform, the Recursion Operating System, and its internal and partnered pipeline. The company reported a positive clinical readout from its REC-4881 program in familial adenomatous polyposis and stated it plans to engage with the FDA in the first half of 2026 to define a potential registration path. Recursion also reported actions taken in 2025 to streamline operations, sharpen portfolio priorities, and reduce projected cash burn while continuing investment in platform capabilities, including AI-enabled clinical development tools. The report highlighted ongoing strategic collaborations and partner payments achieved to date, including work with Roche and Genentech and development programs with Sanofi. The full report can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief on February 27, 2026, and is solely responsible for the information contained therein.